Table 2.
Densities (number/glomerulus) of total leucocytes (OX-1), macrophages (ED1), CD4 and CD8 positive cells, and crescent (%) in glomeruli of each treatment group in WKY rats with crescentic glomerulonephritis on day 14
| Group | OX-1 | ED1 | CD4 | CD8 | Crescent |
|---|---|---|---|---|---|
| Saline | 20·5 ± 0·8 | 17·7 ± 0·8 | 2·0 ± 0·1 | 1·1 ± 0·1 | 43·4 ± 1·8 |
| CA (10mg/kg) | 20·1 ± 0·4 | 18·0 ± 0·3 | 2·0 ± 0·1 | 1·0 ± 0·1 | 42·5 ± 1·4 |
| SCA (5mg/kg) | 17·9 ± 0·4*† | 14·4 ± 0·6*† | 1·9 ± 0·1 | 0·9 ± 0·1 | 35·1 ± 0·7*† |
| SCA (10mg+kg) | 15·9 ± 0·4*†‡ | 12·6 ± 0·5*†‡ | 1·8 ± 0·1 | 0·9 ± 0·1 | 26·5 ± 1·2*†§ |
| mouse IgG (2mg/kg) | 20·2 ± 0·4 | 18·1 ± 0·3 | 2·2 ± 0·1 | 1·2 ± 0·1 | 43·7 ± 1·2 |
| ARP 2–4 (2mg/kg) | 16·3 ± 0·3*¶ | 14·2 ± 0·4*¶ | 2·0 ± 0·1 | 1·0 ± 0·1 | 28·8 ± 1·4*¶ |
| HRL2 (2mg/kg) | 20·6 ± 0·5 | 17·6 ± 0·5 | 2·3 ± 0·1 | 1·2 ± 0·1 | 42·3 ± 1·3 |
| HRL3 (2mg/kg) | 19·5 ± 0·6 | 17·2 ± 0·6 | 2·3 ± 0·1 | 1·2 ± 0·1 | 39·4 ± 1·8 |
| Normal control | 1·2 ± 0·1** | 0·7 ± 0·1** | 0·4 ± 0·1** | 0·2 ± 0·1** | 0** |
Data are mean ± SEM of 8 rats in each group. Numbers in parentheses represent the daily dose of the drug.
P < 0·01 versus saline group
P < 0·01 versus CA group
P < 0·05 versus SCA (5mg/kg) group
P < 0·01 versus SCA (5mg/kg) group
P < 0·01 versus mouse IgG group
P < 0·01 versus saline, CA,SCA (5mg/kg), SCA (10mg/kg), mouse IgG, ARP 2–4, HRL2, and HRL3 group.
CA, colominic acid; SCA, sulphated colominic acid; mouse IgG, used as a control for ARP 2–4; ARP 2–4, neutralizing anti-rat P-selectin mAb; HRL2, non-neutralizing anti-rat L-selectin mAb used as a control for HRL3; HRL3, neutralizing anti-rat L-selectin mAb.